MIB‐1 labeling index as a prognostic factor for patients with follicular lymphoma treated with rituximab plus CHOP therapy

Cancer Science

Eri Yamamoto³  Naoto Tomita³  Seiji Sakata⁴  Naoko Tsuyama¹  Kengo Takeuchi⁴  Yuki Nakajima⁷  Kazuho Miyashita⁵  Takayoshi Tachibana⁷  Hirotaka Takasaki⁶  Masatsugu Tanaka⁷  Chizuko Hashimoto⁶  Hideyuki Koharazawa⁹  Katsumichi Fujimaki⁵  Jun Taguchi⁸  Hiroshi Harano²  Shigeki Motomura⁶ 

[1]Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan

[2]Department of Hematology, Yokosuka City Hospital, Yokosuka, Japan

[3]Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan

[4]Pathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan

[5]Department of Hematology/Immunology, Fujisawa City Hospital, Fujisawa, Japan

[6]Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan

[7]Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan

[8]Department of Hematology, Shizuoka Red Cross Hospital, Shizuoka, Japan

[9]Department of Hematology, Yamato City Hospital, Yamato, Japan

DOI  :  10.1111/cas.12288

来源: Wiley

【 摘 要 】

Abstract

The MIB-1 labeling index, which is based on Ki67 immunostaining, is widely used to evaluate the proliferation of tumor cells in lymphoma. However, its clinical significance has not been fully assessed. We retrospectively evaluated the prognostic impact of the MIB-1 labeling index at the time of diagnosis, in 98 patients with follicular lymphoma (FL) grade 1–3b who were treated uniformly with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy. The 5-year progression-free survival (PFS) for an MIB-1 labeling index of ≥10% (n = 60) and <10% (n = 38) was 35% and 61%, respectively (P = 0.015). The 5-year overall survival (OS) for an MIB-1 labeling index of ≥10% and <10% was 77% and 92%, respectively (P = 0.025). Pathological grading was not correlated with PFS or OS. In multivariate analysis, an MIB-1 labeling index of ≥10% was independently associated with poor PFS and OS. In conclusion, an MIB-1 labeling index of 10% is a useful cut-off level for predicting the prognosis of patients with FL.

【 授权许可】

Unknown   
© 2013 Japanese Cancer Association